Literature DB >> 28102878

Pulmonary hypertension associated with left-sided heart disease.

Micha Tobias Maeder1, Otto D Schoch2, Rebekka Kleiner2, Lucas Joerg1, Daniel Weilenmann1.   

Abstract

Pulmonary hypertension associated with left-sided heart disease (PH-LHD) is the most common type of pulmonary hypertension. In patients with left-sided heart disease, the presence of pulmonary hypertension is typically a marker of more advanced disease, more severe symptoms, and worse prognosis. In contrast to pulmonary arterial hypertension, PH-LHD is characterised by an elevated pulmonary artery wedge pressure (postcapillary pulmonary hypertension) without or with an additional precapillary component (isolated postcapillary versus combined postcapillary and precapillary pulmonary hypertension). Transthoracic echocardiography is the primary nonin-vasive imaging tool to estimate the probability of pulmonary hypertension and to establish a working diagnosis on the mechanism of pulmonary hyperten-sion. However, right heart catheterisation is always required if significant pulmonary hypertension is sus-pected and exact knowledge of the haemodynamic constellation is necessary. The haemodynamic con-stellation (mean pulmonary artery pressure, mean pulmonary artery wedge pressure, left ventricular end-diastolic pressure) in combination with clinical infor-mation and imaging findings (mainly echocardiog-raphy, coronary angiography and cardiac magnetic resonance imaging) will usually allow the exact mech-anism underlying PH-LHD to be defined, which is a prerequisite for appropriate treatment. The general principle for the management of PH-LHD is to treat the underlying left-sided heart disease in an optimal man-ner using drugs and/or interventional or surgical ther-apy. There is currently no established indication for pulmonary arterial hypertension-specific therapies in PH-LHD, and specific therapies may even cause harm in patients with PH-LHD.

Entities:  

Mesh:

Year:  2017        PMID: 28102878     DOI: 10.4414/smw.2017.14395

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  5 in total

1.  The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction.

Authors:  Ying Zhao; Li-Guo Tian; Li-Xin Zhang; Tao Ma; Liang Di; Yan-Bo Wang; Xin-Shun Gu; Dan-Dan Wang; Shang Gao; Haiyan Wang
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886

2.  Pulmonary Hypertension in Aortic and Mitral Valve Disease.

Authors:  Micha T Maeder; Lukas Weber; Marc Buser; Marc Gerhard; Philipp K Haager; Francesco Maisano; Hans Rickli
Journal:  Front Cardiovasc Med       Date:  2018-05-23

3.  Upregulation of miR-361-3p suppresses serotonin-induced proliferation in human pulmonary artery smooth muscle cells by targeting SERT.

Authors:  Ying Zhang; Yongbin Chen; Guo Chen; Yingling Zhou; Hua Yao; Hong Tan
Journal:  Cell Mol Biol Lett       Date:  2020-10-07       Impact factor: 5.787

Review 4.  Pulmonary Hypertension in Patients With Heart Failure With Mid-Range Ejection Fraction.

Authors:  Micha T Maeder; Lukas Weber; Marc Buser; Roman Brenner; Lucas Joerg; Hans Rickli
Journal:  Front Cardiovasc Med       Date:  2021-07-09

5.  Pulmonary hypertension in stiff left atrial syndrome: pathogenesis and treatment in one.

Authors:  Micha T Maeder; Reto Nägele; Philipp Rohner; Daniel Weilenmann
Journal:  ESC Heart Fail       Date:  2017-11-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.